Physician profile
Reena Ranpuria
NPI 1518173608
$10,604.40
in general payments reported to CMS, 2019-2025
31 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $584 · 2021: $1,218 · 2022: $1,697 · 2023: $2,321 · 2024: $2,114 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,000 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,000.22 |
| Education | $139.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,362.13 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $1,224.63 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $976.71 | 2019-2025 | Veltassa, Korsuva |
| Horizon Therapeutics Plc | $696.14 | 2019-2023 | Krystexxa |
| Amgen INC. | $652.17 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $551.83 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $448.33 | 2021-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $437.26 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $431.78 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $400.96 | 2019-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $386.77 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $381.88 | 2019-2025 | Jynarque |
| Mallinckrodt Enterprises LLC | $348.50 | 2019 | |
| Glaxosmithkline, LLC. | $324.90 | 2021-2025 | Benlysta, Jesduvroq |
| Ani Pharmaceuticals, INC. | $284.13 | 2022-2023 | Purified Cortrophin Gel |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $269.69 | 2020-2025 | Auryxia, Vafseo |
| Calliditas Therapeutics US INC. | $251.34 | 2022-2025 | Tarpeyo |
| Lilly USA, LLC | $199.86 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $187.15 | 2023-2025 | Ibsrela |
| Boston Scientific Corporation | $140.03 | 2023 | |
| Scpharmaceuticals INC. | $115.67 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $85.01 | 2024-2025 | Jynarque |
| Alnylam Pharmaceuticals INC. | $73.77 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $70.86 | 2023-2024 | Ultomiris |
| Kyowa Kirin, INC. | $70.26 | 2023-2025 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.24 | 2024 | Jardiance |
| Philips North America LLC | $47.24 | 2023 | |
| Recor Medical INC | $46.34 | 2025 | Paradise Ultrasound Renal Denervation System |
| Genentech USA, INC. | $37.59 | 2019 | |
| Genzyme Corporation | $24.84 | 2020 | |
| Ascendis Pharma Endocrinology INC | $14.39 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Ranpuria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.